<div id="readability-page-1"><p>Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report)'s share price dropped 4.1% during mid-day trading on Tuesday . The company traded as low as $33.58 and last traded at $33.6320. Approximately 39,548 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 1,346,963 shares. The stock had previously closed at $35.06.</p><div><p><span></span><span>Get <strong>Twist Bioscience</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>Several equities analysts have recently weighed in on the stock. Stephens initiated coverage on shares of Twist Bioscience in a research note on Monday, November 3rd. They issued an &#34;overweight&#34; rating and a $41.00 price target on the stock. Evercore ISI cut their price objective on shares of Twist Bioscience from $46.00 to $42.00 and set an &#34;outperform&#34; rating for the company in a report on Tuesday, October 7th. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Twist Bioscience in a report on Monday, December 15th. Finally, Barclays upped their price target on Twist Bioscience from $37.00 to $39.00 and gave the company an &#34;overweight&#34; rating in a research report on Monday, December 15th. Eight research analysts have rated the stock with a Buy rating and two have issued  a Sell rating to the company's stock. According to data from MarketBeat.com, the company  has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $44.88.</p><p><b>Get Our Latest Stock Analysis on Twist Bioscience</b></p><h2>Twist Bioscience Trading Down 4.3%</h2><p>The company's 50 day simple moving average is $31.02 and its two-hundred day simple moving average is $31.19. The company has a market cap of $2.05 billion, a PE ratio of -25.66 and a beta of 2.24. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.64 and a quick ratio of 3.33. </p><p>Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. The company had revenue of $99.01 million during the quarter, compared to analyst estimates of $97.40 million.  As a group, sell-side analysts anticipate that  Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year. </p><h2>Insider Activity at Twist Bioscience</h2><p>In other Twist Bioscience news, CEO Emily M. Leproust sold 4,887 shares of the stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total transaction of $156,774.96. Following the sale, the chief executive officer directly owned 733,922 shares in the company, valued at $23,544,217.76. This represents a 0.66% decrease in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,084 shares of the company's stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total value of $34,774.72. Following the sale, the senior vice president directly owned 142,187 shares in the company, valued at $4,561,358.96. This represents a 0.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 116,878 shares of company stock valued at $3,721,723. 3.01% of the stock is owned by company insiders. </p><h2>Institutional Investors Weigh In On Twist Bioscience</h2><p>Large investors have recently bought and sold shares of the stock. Quarry LP acquired a new position in shares of  Twist Bioscience during the third quarter worth about $28,000.  Smartleaf Asset Management LLC increased its position in shares of  Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock valued at $29,000 after purchasing an additional 442 shares during the last quarter.  National Bank of Canada FI purchased a new stake in shares of  Twist Bioscience in the 3rd quarter valued at approximately $46,000.  Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of  Twist Bioscience by 15.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after purchasing an additional 302 shares in the last quarter.  Finally, Geneos Wealth Management Inc. purchased a new stake in shares of  Twist Bioscience during the 2nd quarter worth $97,000. </p><h2>Twist Bioscience Company Profile</h2> (Get Free Report)<p>Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.  </p><p>At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Twist Bioscience</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Elon Warns “America Is Broke”. Trump’s Plan Inside.</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Twist Bioscience Right Now?</h2><p>Before you consider Twist Bioscience, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Twist Bioscience wasn't on the list.</p><p>While Twist Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TWST

<p>Twist Bioscience's stock (NASDAQ:TWST) fell 4.1% during mid-day trading, with a significant drop in trading volume. Analysts have mixed ratings, with some maintaining 'Buy' and others 'Sell'. The company reported a quarterly loss, missing estimates, and insiders have sold shares recently. Institutional investors have adjusted their positions, with some increasing holdings. Twist Bioscience specializes in DNA-based products, using a proprietary synthesis platform.</p>

Twist Bioscience (NASDAQ:TWST) Stock Price Down 4.1% - Time to Sell?